GT Biopharma (GT Biopharma) Cash-to-Debt : 326.90 (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is GT Biopharma Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. GT Biopharma's cash to debt ratio for the quarter that ended in Mar. 2024 was 326.90.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, GT Biopharma could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for GT Biopharma's Cash-to-Debt or its related term are showing as below:

GTBP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.21 Max: 1274.36
Current: 326.9

During the past 13 years, GT Biopharma's highest Cash to Debt Ratio was 1274.36. The lowest was 0.00. And the median was 0.21.

GTBP's Cash-to-Debt is ranked better than
84.06% of 1493 companies
in the Biotechnology industry
Industry Median: 6.89 vs GTBP: 326.90

GT Biopharma Cash-to-Debt Historical Data

The historical data trend for GT Biopharma's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

GT Biopharma Cash-to-Debt Chart

GT Biopharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.20

1,031.58

94.87

240.90

GT Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															135.37	149.78	174.07	240.90	326.90

Competitive Comparison of GT Biopharma's Cash-to-Debt

For the Biotechnology subindustry, GT Biopharma's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GT Biopharma's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Cash-to-Debt falls into.

GT Biopharma Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

GT Biopharma's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	13.972	/	(0.058	+	0)
	=	240.90

GT Biopharma's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	9.807	/	(0.03	+	0)
	=	326.90

GT Biopharma (NAS:GTBP) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

GT Biopharma Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of GT Biopharma's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

GT Biopharma (GT Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GT Biopharma Inc (NAS:GTBP) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

OXI1:Germany

Address

8000 Marina Boulevard, Suite 100, Brisbane, CA, USA, 94005

Website

https://www.gtbiopharma.com

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Executives

Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Michael Martin Breen	director, officer: Exec. Chair. and Interim CEO	LOWSLEY HOUSE 133 HEADLEY ROAD, LIPHOOK X0 GU30 7PU
Manu Ohri	officer: CFO & Secretary	2355 MAIN STREET, SUITE 120, IRVINE CA 92614
Bruce Wendel	director	70 ELEVEN O'CLOCK ROAD, WESTON CT 06883
Gregory Berk	officer: Pres. of R&D, CMO	HANA BIOSCIENCES, INC., 400 OYSTER POINT BLVD, SAN FRANCISCO CA 94080
Shrotriya Rajesh C Md	director	157 TECHNOLOGY DRIVE, IRVINE CA 92618
Alan Louis Urban	director	1524 CLOVERFIELD BOULEVARD, SUITE E, SANTA MONICA CA 90404
Gavin Choy	officer: Acting Chief Financial Officer	8000 MARINA BLVD, STE. 100, C/O GT BIOPHARMA, INC., BRISBANE CA 94005
Steven W Weldon	director, officer: CFO	7280 WESTPOINTE BLVD, APT 831, ORLANDO FL 32835
Shawn Cross	director, officer: Chief Executive Officer	1825 K STREET SUITE 510, WASHINGTON DC 20006
Raymond W. Urbanski	officer: Chief Medical Officer	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Kathleen Clarence-smith	director, 10 percent owner, officer: CEO	1623 31ST STREET NW, WASHINGTON DC 20007
Mark J Silverman	10 percent owner	224 22ND ST., SANTA MONICA CA 90402
Bristol Capital Llc	10 percent owner
Bristol Investment Fund Ltd	10 percent owner	89 NEXUS WAY, CAMANA BAY, PO BOX 311063, GRAND CAYMAN E9 KY1-1205